drugset / Trial / NCT01152190

A Study in Benign Prostatic Hyperplasia

NCT01152190

Phase 3 Completed 97 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.

Timeline

Start
2010-09
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral